its higher stability in comparison with the mammalian enzyme. The enzyme was reconstituted in 0.2 M citratephosphate buffer, pH 5.0 (= pH optimum of GAD from E. coli) with 0.05 % sodium azide. VÚFB 19369, 19370, 19371, and 19760 . GAD: The enzyme solution (concentrations 56.25, 11.25, and 5.62 mg prot/l in different experiments) was incubated with 1 x 10 -3 M suspensions of individual compounds (representing saturated solutions during the whole time of incubation) for 14 days at room temperature (25°C). Time profiles of enzyme activities were monitored.
Enzyme assays
Aminotransferase activities were determined by the kinetic UV method with addition of pyridoxal-5'-phosphate to the incubation mixture (Roche Diagnostics, Mannheim, Germany, transaminating catalytic activity combined with lactate or malate dehydrogenase reaction) common in clinical chemistry laboratories (1, 2) . Sample aliquots (100 µl) were diluted (ALT) or (AST) with 0.05 M phosphate buffer, pH 7.4, in order to obtain catalytic activities within the analytical range of the employed method. The enzyme activities were assayed on a Hitachi 917 analyzer. All experiments were performed in triplicates. ALT and AST catalytic activities in Precinorm U and Precipath U (both from Roche Diagnostics) were measured before and after each assay. The between-run coefficients of variation of the both assays for Precinorm U and Precipath U were lower than 2.0 %. GAD activity was assayed by the radiometric method with 1-14 C-glutamate as the substrate (4). The incubation mixture contained the enzyme, substrate L-glutamate-1-14 C, coenzyme pyridoxal-5'-phosphate, and the compounds tested. The mixture was incubated at 37°C for 30 min and the radioactivity of 14 CO 2 liberated from the mixture and trapped by means of 0.1 ml of 30 % KOH was measured in a scintillation cocktail using a 1219 Rackbeta scintillation counter LKB Wallac (Radioisotope Laboratory, Faculty of Pharmacy, Charles University, Hradec Králové).
Results and Discussion

Aspartate and alanine aminotransferase
Results are summarized in Table 1 and Table 2 . No immediate inhibition of aminotransferases ALT and AST by any potential NSAID compound studied was found.
No significant changes in aminotransferase activities were found during incubation of the enzyme with individual members of a group of phenylsulfanylbenzoic acid derivatives: VÚFB 19363 in 6 x 10 -5 M concentration, VÚFB 19369, 19370, 19371 , and 19760 in 8 x 10 -5 M concentration. Some gradual decrease in AST activity was found with 5 x 10 -2 M suspension of the compound VÚFB 19363. We suggest that some partial inactivation of the enzyme protein takes place when a high concentration of the compound is available for reaction with the enzyme protein. This effect is comparable with that found in our study of a group of natural compounds under similar conditions (3).
2.Glutamate decarboxylase
Various conditions were used in order to investigate the influence of compounds under study on GAD in vitro: No immediate inhibition of GAD by any potential NSAID compound studied was found at any enzyme protein concentration used.
In spite of the fact that the enzyme was reconstituted in the same way for each experiment, final specific activities of GAD expressed as the activity per declared protein concentration in samples were not identical (see Table 3 , in which the results are summarized).
Some changes in GAD activity during a longer incubation with 1 x 10 -3 M suspensions of individual compounds (including "activation" of GAD) were found. Striking is an increasing effect of compounds studied accompanying a decreasing concentration of the enzyme protein (compare Fig. 2 to Fig. 4 ), which suggests that more probably some irreversible interferences of the compounds studied with enzyme molecules take part than the "classical" reversible inhibition or activation of enzymes.
Because of differences in the control activities of GAD found in the individual experiments, we tried to recalculate the results of investigations as percentage of control activi- Inhibition, Inhibition, Inhibition, Activation 0 0 Activation independent independent independent of time of time of time 0 = no effect; -= not ties, which enabled us to express and compare the results of different experiments in which the same concentrations of the enzyme were used (Fig. 2-4 ). Even at longer intervals, no significant effect of any compound studied was found when the highest concentration of GAD (56,25 mg/ml) was used (Fig. 2) . With a decreasing concentration of GAD, differences appeared, which were not significant but were more marked during later intervals of experiments: A certain non-significant decrease in GAD activity was found with the compound VÚFB 19363 with protein concentrations 11.25 and 5.62 mg prot/l, and a small relative increase in GAD activity in comparison with controls in the case of other compounds with a protein concentration of 5.62 mg prot/l ( Fig. 3 and 4) . When the absolute results are analyzed, it is obvious that the effect is caused by decreasing GAD control activities, while the enzyme activities in the presence of compounds VÚFB 19370, 19371, and 19760 are more stable (see Fig. 5 ).
Conclusions
No immediate inhibition of aminotransferases and GAD
by the compounds VÚFB 19363, 19369, 19370, 19371 , and 19760 was found. 2. Incubation of aminotransferases or GAD with the compound VÚFB 19363 under various conditions caused no significant changes in the activities of these enzymes. 3. In the case of compounds VÚFB 19369, 19370, 19371, and 19760 there was a tendency to stabilize GAD. 4. The lack of immediate effect of the compounds VÚFB 19363, 19369, 19370, 19371, and 19760 , and the stability of the enzymes during their incubation with the compounds VÚFB 19369, 19370, 19371 , and 19760 are favorable and support the prospective of further testing and using these compounds as potential drugs.
